Get the Stockscreener App
34.42
1.89%
0.64
Pre-market:
33.81
-0.61
-1.77%
Stoke Therapeutics Inc stock is traded at $34.42, with a volume of 517.14K.
It is up +1.89% in the last 24 hours and up +7.56% over the past month.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
See More
Previous Close:
$33.78
Open:
$34.41
24h Volume:
517.14K
Relative Volume:
0.71
Market Cap:
$1.97B
Revenue:
$199.89M
Net Income/Loss:
$52.48M
P/E Ratio:
40.49
EPS:
0.85
Net Cash Flow:
$61.15M
1W Performance:
-3.04%
1M Performance:
+7.56%
6M Performance:
+75.34%
1Y Performance:
+354.09%
1-Day Range:
$32.70
$34.98
1-Week Range:
$32.70
$39.81
52-Week Range:
$5.35
$39.81
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
34.42 | 1.93B | 199.89M | 52.48M | 61.15M | 0.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | Guggenheim | Buy |
| Jan-05-26 | Resumed | Chardan Capital Markets | Buy |
| Jul-18-25 | Initiated | Jefferies | Buy |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
Insider Sell: Adrian Krainer Sells 7,229 Shares of Stoke Therape - GuruFocus
Biogen (BIIB) Reports Promising Data on Zorevunersen for Dravet Syndrome - GuruFocus
The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome - The AI Journal
Stoke Therapeutics and Biogen Announce Promising Results for Zorevunersen in Treating Dravet Syndrome, Supporting Phase 3 EMPEROR Study - Quiver Quantitative
Stoke Therapeutics (STOK) director sells 7,229 shares under 10b5-1 plan - Stock Titan
Stoke Therapeutics grants $697,125 bonus to CEO Ian F. Smith By Investing.com - Investing.com Australia
Stoke Therapeutics grants $697,125 bonus to CEO Ian F. Smith - Investing.com South Africa
Stoke Therapeutics Awards Discretionary Bonus to CEO Smith - TipRanks
Stoke Therapeutics (NASDAQ: STOK) awards CEO Ian F. Smith $697,125 2025 bonus equivalent - Stock Titan
STOK: Phase 3 Dravet study nears full enrollment, with strong efficacy and broad market potential - TradingView
STOK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[144] Stoke Therapeutics, Inc. SEC Filing - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Sets New 1-Year HighWhat's Next? - MarketBeat
Stoke Therapeutics stock hits 52-week high at 38.8 USD By Investing.com - Investing.com Canada
Stoke Therapeutics stock hits 52-week high at 38.8 USD - Investing.com India
Portfolio Shifts: What dividend growth rate does Stoke Therapeutics Inc offerJuly 2025 Levels & Real-Time Market Sentiment Alerts - baoquankhu1.vn
(STOK) Movement as an Input in Quant Signal Sets - Stock Traders Daily
STOK PE Ratio & Valuation, Is STOK Overvalued - Intellectia AI
Stoke Therapeutics (STOK) Investor Outlook: A Promising Biotech with 17.3% Upside Potential - DirectorsTalk Interviews
Stoke Therapeutics Opens with 6.45% Gain, Outperforming S&P 500's 0.69% - Markets Mojo
Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Wolfe Research - MarketBeat
Risk Analysis: What is the earnings history of Stoke Therapeutics IncJuly 2025 Outlook & Weekly High Return Opportunities - baoquankhu1.vn
Stoke Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - PharmiWeb.com
Stoke Therapeutics stock swings premarket after Wolfe starts coverage with $40 target (STOK) - TechStock²
Wolfe Research Initiates Coverage on Stoke Therapeutics (STOK) w - GuruFocus
Wolfe Research Initiates Coverage of Stoke Therapeutics (STOK) with Outperform Recommendation - Nasdaq
Forecasting The Future: 5 Analyst Projections For Stoke Therapeutics - Benzinga
A Look At Stoke Therapeutics (STOK) Valuation After Recent Share Price Momentum - Yahoo Finance
Stoke Therapeutics Shares Poised for Pivotal Clinical Updates - AD HOC NEWS
Is Stoke Therapeutics Inc. stock a good pick for beginnersJuly 2025 Big Picture & Real-Time Stock Entry Alerts - mfd.ru
What is the PEG ratio of Stoke Therapeutics Inc.July 2025 Earnings & AI Enhanced Trading Alerts - mfd.ru
Stoke Therapeutics, Inc. (STOK) Stock Analysis: Impressive Revenue Growth and Promising Upside - DirectorsTalk Interviews
Is Stoke Therapeutics Inc. in a long term uptrend2025 Price Momentum & Free Low Drawdown Momentum Trade Ideas - mfd.ru
STOK: Cantor Fitzgerald Analyst to Host Conference Call with Man - GuruFocus
Stoke Therapeutics (NASDAQ: STOK) awards options and RSUs to counsel - Stock Titan
Stoke Therapeutics (NASDAQ:STOK) Stock Price Up 10.2%Here's Why - MarketBeat
45,205 Shares in Stoke Therapeutics, Inc. $STOK Acquired by Principal Financial Group Inc. - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Liquidity Mapping Around (STOK) Price Events - Stock Traders Daily
Growth Value: What are the analyst revisions for MESAIs Stoke Therapeutics Inc stock a good investment in YEARPortfolio Gains Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Needham Maintains Stoke Therapeutics (STOK) Buy Recommendation - MSN
Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit - MarketBeat
Stoke Therapeutics, Inc. (STOK) Stock Analysis: Unveiling a 31% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Ideas Watch: What is the earnings history of Stoke Therapeutics IncQuarterly Trade Review & AI Enhanced Market Trend Forecasts - baoquankhu1.vn
STOK: Four-year data show durable seizure reduction and cognitive gains, with phase 3 readout expected 2027 - TradingView
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Mo - pharmiweb.com
Stoke Therapeutics announces first patient dosed in Phase 1 study of STK-002 - marketscreener.com
Is Stoke Therapeutics Inc. a cyclical or defensive stockQuarterly Earnings Report & Daily Technical Forecast Reports - mfd.ru
Stoke Therapeutics announced that the dose-escalation phase for the first four cohorts of its research project will continue into 2026 and early 2027. - Bitget
Stoke Therapeutics Announces First Patient Dosed In Phase 1 Study Of Stk-002 - TradingView
Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA) - Business Wire
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):